Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

Table 4 Five years (%) OS (overall survival), PFS (progression-free survival), (distant metastasis-free survival), LRRFS (locoregional relapse-free survival) and HRs with 95% CI

	CCRT plus cetuximab group (%)	CCRT group (%)	Hazard ratio^a	P value
	N = 62	N = 124	(95% CI)
Overall survival
Deaths	6	11	_
Rate at 5 years	89.7%	90.7%	0.705	0.386
Rate at 5 years	(81.9–97.5)	(85.4–96.0)	(0.318–1.560)	0.386
Progression-free survival
Progression	13	19	_
Rate at 5 years	77.6%	84.5%	0.607	0.115
Rate at 5 years	(66.6–88.5)	(78.0–91.0)	(0.324–1.137)	0.115
Locoregional relapse-free survival
Locoregional relapses	3	7	_
Rate at 5 years	95.0%	94.0%	0.803	0.695
Rate at 5 years	(89.5–100)	(89.7–98.3)	(0.269–2.403)	0.695
Distant metastasis-free survival
Distant metastases	10	12	_
Rate at 5 years	82.0%	90.3%	0.489	0.068
Rate at 5 years	(71.8–92.2)	(85.0–95.6)	(0.223–1.072)	0.068

Data are n (%) or rate (95% CI). ^aHazard ratios were calculated with the unadjusted Cox proportional hazards model. P values were calculated with the unadjusted log-rank test

ISSN: 1471-2407